Minoryx Therapeutics BE
0713.984.534 · rovalta.com · 25/09/2026
ACTIVE
Minoryx Therapeutics BE
Financial year 2025 · Closed on 31/12/2025
Net result-1,1 M €+31,2 %over 1 year
Gross margin242,4 k €-44,2 %over 1 year
Equity2,6 M €-42,4 %over 1 year
Workforce4,8 ETP-17,2 %over 1 year
Overview
Identity
Source · BCE/KBOMinoryx Therapeutics BE is a Public limited company incorporated in 2018. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi. It employs on average 4,8 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0713.984.534
- Incorporation
- 28/11/2018
- Legal form
- Public limited company
- Registered office
- Avenue Jean Mermoz 32 box 6
6041 Charleroi · WallonieSee on map - Contributed capital
- 5 285 156,00 €
- Latest accounts
- 31/12/2025
- Average workforce
- 4,8 ETP
Activities (NACE)
72109Research and experimental development on natural sciences and engineering· main72190Other research and experimental development on natural sciences and engineering21100Manufacture of basic pharmaceutical products21100Manufacture of basic pharmaceutical products71209Technical testing and analysis71209Technical testing and analysis+4
Joint committees (1)
- 207
Signals
Solid equityGood liquidityPositive cashflowHealthy social debts
Financials
Source · NBB, 8 filingsTrend over 8 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 242,4 k € | -44.2% | 434,3 k € | +56.7% | 277,2 k € | +669% | -48,7 k € | +71.8% | -172,5 k € |
| EBITDA | -498,2 k € | +0.7% | -501,5 k € | -47.8% | -339,3 k € | +39.5% | -560,5 k € | +18.3% | -686,1 k € |
| Operating result | -2,1 M € | +24.0% | -2,8 M € | -21.7% | -2,3 M € | -4.6% | -2,2 M € | -4.8% | -2,1 M € |
| Net result | -1,1 M € | +31.2% | -1,6 M € | -9.3% | -1,4 M € | -0.6% | -1,4 M € | -4.3% | -1,4 M € |
| Balance sheet | |||||||||
| Equity | 2,6 M € | -42.4% | 4,4 M € | -36.6% | 7 M € | +42.1% | 4,9 M € | +13.2% | 4,3 M € |
| Total assets | 3,9 M € | -31.4% | 5,6 M € | -28.4% | 7,9 M € | +26.4% | 6,2 M € | +5.1% | 5,9 M € |
| Cash | 240,3 k € | -17.3% | 290,5 k € | -68.1% | 910,5 k € | +190% | 313,6 k € | +1210% | 23,9 k € |
| Debts | 1,3 M € | +9.2% | 1,2 M € | +36.2% | 883,3 k € | -32.6% | 1,3 M € | -17.1% | 1,6 M € |
| Other | |||||||||
| Workforce | 4,8 ETP | -17.2% | 5,8 ETP | +13.7% | 5,1 ETP | +34.2% | 3,8 ETP | -17.4% | 4,6 ETP |
Valuation
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20252 active · 6 ended
Active mandates
Marc Martinell Pedemonte
ActiveActive
Ended mandates
Didier Le Normand
EndedDidier Le Normand
EndedLe Normand Didier
EndedMarc Martinell Pedemonte
EndedOther companies at this address
Avenue Jean Mermoz 32 6041 Charleroi| Company | CBE no. |
|---|---|
EGEIRO PHARMA● Bankrupt | 0684.906.013 |
IPRATECH● Active | 0893.778.586 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 22/07/2026 | 22/06/2025 | 23/06/2024 | 27/06/2023 | 13/07/2022 | 22/07/2021 |
| General meeting | 29/05/2026 | 30/05/2025 | 31/05/2024 | 31/05/2023 | 15/06/2022 | 30/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 8 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 29/05/2026 | 22/07/2026 | French | |
| Abridged model | 31/12/2024 | 30/05/2025 | 22/06/2025 | French | |
| Abridged model | 31/12/2023 | 31/05/2024 | 23/06/2024 | French | |
| Abridged model | 31/12/2022 | 31/05/2023 | 27/06/2023 | French | |
| Abridged model | 31/12/2021 | 15/06/2022 | 13/07/2022 | French | |
| Micro model | 31/12/2020 | 30/06/2021 | 22/07/2021 | French | |
| Micro model | 31/12/2019 | 18/06/2020 | 12/07/2020 | French | |
| Abridged model | 31/12/2018 | 31/05/2019 | 28/06/2019 | French |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20252 active · 6 ended
Active mandates
Marc Martinell Pedemonte
ActiveActive
Ended mandates
Didier Le Normand
EndedDidier Le Normand
EndedLe Normand Didier
EndedMarc Martinell Pedemonte
EndedOwnership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Capital / shares25/06/2026STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates12/12/2023STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
- Registered office23/03/2023SIEGE SOCIAL
- Capital / shares09/12/2022STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates13/12/2021DEMISSIONS, NOMINATIONS
- Other09/11/2020STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Mandates01/07/2019DEMISSIONS, NOMINATIONS
- Mandates06/05/2019CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-1,1 M €↑
- 2024Annual accounts 2024-1,6 M €↓
- 2024Name changeMinoryx Therapeutics
- 2023Annual accounts 2023-1,4 M €↓
- 2022Annual accounts 2022-1,4 M €↓
- 2021Annual accounts 2021-1,4 M €↓
- 2020Annual accounts 2020770,2 k €↑
- 2019Annual accounts 2019-2,7 M €↓
- 2018Annual accounts 2018-3,7 k €
- 28/11/2018IncorporationPublic limited company
- 2018Name changeMinoryx Therapeutics BE